RashnaMadanMD
Pathology • Kansas City, KSCytopathology, Anatomic Pathology, Clinical Pathology
Assistant Professor, Pathology and Laboratory Medicine, University Kansas School of Medicine
Are you Dr. Madan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 24 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4000 Cambridge St
Kansas City, KS 66160Phone+1 913-588-1227Fax+1 913-588-7073
Summary
- Dr. Rashna Madan, MD is a board certified pathologist in Kansas City, Kansas. She is currently licensed to practice medicine in Kansas and Connecticut. She is affiliated with The University of Kansas Hospital and is an Assistant Professor at University Kansas School of Medicine.
Education & Training
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 2006 - 2007
Memorial Sloan Kettering Cancer Center Oncologic PathologyFellowship, Selective Pathology, 2005 - 2006- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 2001 - 2005
Kasturba Medical College ManipalClass of 1997
Certifications & Licensure
KS State Medical License 2007 - 2025
CT State Medical License 2005 - 2008- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Cytopathology
Publications & Presentations
PubMed
- 376 citationsProteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung AdenocarcinomaMichael A. Gillette, Shankha Satpathy, Song Cao, Saravana M. Dhanasekaran, Suhas Vasaikar
Cell. 2020-07-09 - 312 citationsProteogenomic and metabolomic characterization of human glioblastomaLiang-Bo Wang, Alla Karpova, Marina A. Gritsenko, Jennifer E. Kyle, Song Cao
Cancer Cell. 2021-04-12 - 22 citationsClinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.Priyanka Sharma, Shane R Stecklein, Rachel Yoder, Joshua M Staley, Kelsey Schwensen
JAMA Oncology. 2024-02-01
Press Mentions
Targeted Inhibition of Histone Deacetylase Leads to Suppression of Ewing Sarcoma Tumor Growth Through an Unappreciated EWS-FLI1/HDAC3/HSP90 Signaling AxisApril 25th, 2019
